India Pharmaceuticals Industry Analysis and Trends 2023
India pharmaceutical market was the 11th largest pharmaceuticals market by value in the world in 2017. It is expected to register second highest CAGR growth among all countries till 2023 and improve it’s raking to reach 9th position in the global pharmaceuticals market. Indian pharmaceutical market is expected to grow in the upcoming years despite recent slowdown due to price erosion in U.S. generics pharmaceuticals market, delay in approval of complex generics by US FDA (United States Food and Drug Administration) and aggressive drug price control mechanism like Government mandated drug price controls using drug price control order (DPCO) which is an order issued by the Government of India under Section 3 of the Essential Commodities Act, 1955 empowering it to fix and regulate the prices of essential bulk drugs and their formulations. The reasons are simple: aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases.
As per NAVADHI Market Research, the India pharmaceutical industry will we worth USD 33.18 billion and will rank 9th in global pharmaceuticals market by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
This growth is fueled by the growing and ageing population in India. More than 6% of Indian population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families is also driving the growth of Indian pharma industry. Indian people spend 64.21% of their health expenditure from out-of-pocket of which pharmaceuticals spend accounts for 51.67%. Other factors which are expected to contribute in the growth of Indian pharmaceuticals market are initiatives by Government of India like Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana and Pradhan Mantri Jan Arogya Yojana (PMJAY). In 2018, Government of India launched the world’s largest public healthcare scheme Ayushman Bharat Yojana or Pradhan Mantri Jan Arogya Yojana (PMJAY) under National Health Protection Scheme (NHPS) which aims to provide free healthcare coverage of up to INR 0.5 million to around 100 million people. Also, under the aegis of Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana the Government of India as set up Jan Aushadhi Kendra (pharmacy stores) which provide quality medicines at affordable prices. These factors are expected to increase the access of pharmaceuticals to more people in world’s second most populous nation.
On the other hand, Indian government’s plan to widen the drug price control policies to patented and rare disease drugs along with tightening of rules by U.S. government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market (which is a major market for Indian pharmaceuticals companies) are expected to impact the growth prospect of the Indian pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the Indian pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
U.S., South Africa, United Kingdom, Nigeria and Russia were the top five countries importing Indian pharmaceuticals and accounted for 48.58% of the total export revenues earned by Indian pharmaceutical industry in 2018.
The top ten Indian pharmaceutical importing countries (including Brazil, Australia, Kenya, Nepal and Philippines) accounted for 56.68% of the total export revenues earned by Indian pharmaceutical industry in 2018.
U.S., Germany, Switzerland, China and France were the top five countries exporting pharmaceutical products to Indian market and accounted for 48.80% of the total imports by Indian pharmaceutical industry in 2018.
The top ten Indian pharmaceutical importing countries (including Denmark, Belgium, Italy, Brazil and Indonesia) accounted for 71.77% of the total imports by Indian pharmaceutical market in 2018.
Navadhi has provided detailed company profiles including their position in Indian pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Indian pharmaceuticals market namely: Abbott India Limited, Aurobindo Pharma Limited, Biocon Limited, Cipla Limited, Divis Laboratories Limited, Dr. Reddy’s Laboratories, IPCA Laboratories Limited, Lupin Limited, Sun Pharmaceuticals Limited and Torrent Pharmaceuticals Limited.
Scope of the India Pharmaceuticals Industry Analysis and Trends 2023 Report
As per NAVADHI Market Research, the India pharmaceutical industry will we worth USD 33.18 billion and will rank 9th in global pharmaceuticals market by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
This growth is fueled by the growing and ageing population in India. More than 6% of Indian population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families is also driving the growth of Indian pharma industry. Indian people spend 64.21% of their health expenditure from out-of-pocket of which pharmaceuticals spend accounts for 51.67%. Other factors which are expected to contribute in the growth of Indian pharmaceuticals market are initiatives by Government of India like Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana and Pradhan Mantri Jan Arogya Yojana (PMJAY). In 2018, Government of India launched the world’s largest public healthcare scheme Ayushman Bharat Yojana or Pradhan Mantri Jan Arogya Yojana (PMJAY) under National Health Protection Scheme (NHPS) which aims to provide free healthcare coverage of up to INR 0.5 million to around 100 million people. Also, under the aegis of Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana the Government of India as set up Jan Aushadhi Kendra (pharmacy stores) which provide quality medicines at affordable prices. These factors are expected to increase the access of pharmaceuticals to more people in world’s second most populous nation.
On the other hand, Indian government’s plan to widen the drug price control policies to patented and rare disease drugs along with tightening of rules by U.S. government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market (which is a major market for Indian pharmaceuticals companies) are expected to impact the growth prospect of the Indian pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the Indian pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
U.S., South Africa, United Kingdom, Nigeria and Russia were the top five countries importing Indian pharmaceuticals and accounted for 48.58% of the total export revenues earned by Indian pharmaceutical industry in 2018.
The top ten Indian pharmaceutical importing countries (including Brazil, Australia, Kenya, Nepal and Philippines) accounted for 56.68% of the total export revenues earned by Indian pharmaceutical industry in 2018.
U.S., Germany, Switzerland, China and France were the top five countries exporting pharmaceutical products to Indian market and accounted for 48.80% of the total imports by Indian pharmaceutical industry in 2018.
The top ten Indian pharmaceutical importing countries (including Denmark, Belgium, Italy, Brazil and Indonesia) accounted for 71.77% of the total imports by Indian pharmaceutical market in 2018.
Navadhi has provided detailed company profiles including their position in Indian pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Indian pharmaceuticals market namely: Abbott India Limited, Aurobindo Pharma Limited, Biocon Limited, Cipla Limited, Divis Laboratories Limited, Dr. Reddy’s Laboratories, IPCA Laboratories Limited, Lupin Limited, Sun Pharmaceuticals Limited and Torrent Pharmaceuticals Limited.
Scope of the India Pharmaceuticals Industry Analysis and Trends 2023 Report
- This report provides detailed information about Indian pharmaceuticals market including future market forecasts up to 2023.
- This report identifies the need for focusing on Indian pharmaceuticals market.
- The report identifies the growth drivers and inhibitors for Indian pharmaceuticals market.
- This report provides information about policies related to pharmaceuticals industry in India.
- This report provides information about industry associations and government bodies related to Indian pharmaceuticals industry.
- The report identifies various risks associated with Indian pharmaceuticals market.
- This report has detailed profiles 10 key players in Indian pharmaceuticals market covering their position in pharmaceuticals value chain, business strategy, financial performance, future forecasts and SWOT analysis.
- This report provides competitive landscape among 10 key companies in Indian pharmaceuticals market.
- This report provides PESTEL (political, economic, social, technological, environmental and legal) analysis for Indian pharmaceuticals market.
- This report provides Porter’s Five Forces analysis for Indian pharmaceuticals market.
- This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Indian pharmaceuticals market.
- This report provides information about current and future trends for Indian pharmaceuticals market.
- This report provides information about current and future trends for U.S. pharmaceuticals market.
1. EXECUTIVE SUMMARY
Scope of the India Pharmaceuticals Industry Analysis and Trends 2023 Report
Research Methodology
2. INTRODUCTION OF INDIAN PHARMACEUTICALS MARKET
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Indian Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR INDIAN PHARMACEUTICALS MARKET
3.1 Rising & Ageing Population
3.2 Increasing Income Levels of Poor & Middle-Class Families
3.3 Drug Security
4. FORECAST FOR INDIA PHARMACEUTICALS MARKET 2023
4.1 Forecast for Asia Pacific Pharmaceuticals Market 2018-2023
4.1.1 Forecast for India Pharmaceuticals Market 2018-2023
5. EXIM SCENARIO IN INDIAN PHARMACEUTICALS MARKET
5.1 Export Scenario of Indian Pharmaceutical Products Market
5.1.1 Value of Pharmaceutical Products Exports from India 2008-09 to 2018-19 (Apr-Jan) in USD million
5.1.2 Top 5 Nations Importing Indian Pharmaceutical Products
5.2 Import Scenario of Indian Pharmaceutical Products Market
5.2.1 Value of Pharmaceutical Products Imports in India 2008-09 to 2018-19 (Apr-Jan) in USD million
5.2.2 Top 5 Nations Exporting Pharmaceutical Products to India
6. GROWTH DRIVERS AND INHIBITORS FOR INDIA PHARMACEUTICALS MARKET
7. POLICIES RELATED TO PHARMACEUTICALS INDUSTRY IN INDIA
7.1 Central Government Policies
7.1.1 Essential Commodities Act 1955
7.1.2 Drugs and Cosmetics Act 1940 (As amended in June 2005)
7.1.3 National Pharmaceutical Pricing Policy 2012
7.1.4 Drug Price Control Orders (DPCO)
7.1.5 Drug Policy 1986
7.1.6 Pharmaceutical Policy - 2002
7.2 Guidelines related to Clinical Trial in India
7.3 Guidelines related to Marketing in Indian Pharmaceuticals Industry
8. RISKS ASSOCIATED WITH INDIAN PHARMACEUTICALS MARKET
8.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
8.2 Risk of Commercial Success of New Products
8.3 Risk of Failed Research and Development Effort
8.4 Risk of Drug Price Controls
8.5 Risk of Failure to Comply with New Laws and Regulations
8.6 Risk of Quality Control During Complex Manufacturing Process
8.7 Risk of Cyber-Attacks and Data Breach
8.8 Risk of Volatile Currency Exchange Rates and Interest Rates
8.9 Risk of Unstable Global Political and Economic Conditions
9. INDUSTRY ASSOCIATIONS RELATED TO INDIAN PHARMACEUTICALS MARKET
9.1 Indian Drug Manufacturers' Association (IDMA)
9.2 Indian Pharma Machinery Manufacturers Association (IPMMA)
9.3 Indian Pharmaceutical Association (IPA)
9.4 Organisation of Pharmaceutical Producers of India (OPPI)
9.5 Association of Indian Medical Device Industry (AIMED)
10. GOVERNMENT BODIES RELATED TO INDIAN PHARMACEUTICALS MARKET
10.1 Department of Pharmaceuticals
10.2 Ministry of Chemicals & Fertilizers
10.3 National Pharmaceutical Pricing Authority (NPPA)
11. PROFILE OF KEY PLAYERS IN INDIAN PHARMACEUTICALS MARKET
11.1 Abbott India Limited
11.1.1 Company Profile
11.1.2 Abbott India in Pharma Manufacturing Value Chain
11.1.3 Abbott India: Financial Performance
11.1.4 Abbott India: Business Strategy
11.1.4.1 Product Level Strategy
11.1.5 SWOT Analysis of Abbott India
Strengths
Weaknesses
Opportunities
Threats
11.1.6 Key Customers of Abbott India
11.2 Biocon Limited
11.2.1 Company Profile
11.2.2 Biocon Limited in Pharmaceutical Manufacturing Value Chain
11.2.3 Biocon Limited: Financial Performance
11.2.4 Biocon Limited: Business Strategy
11.2.4.1 Product Level Business Strategy
11.2.4.2 Service Level Business Strategy
11.2.5 SWOT Analysis of Biocon Limited
Strengths
Weaknesses
Opportunities
Threats
11.2.6 Key Customers of Biocon Limited
11.3 CIPLA Limited
11.3.1 Company Profile
11.3.2 CIPLA Limited in Pharmaceutical Manufacturing Value Chain
11.3.3 CIPLA Limited: Financial Performance
11.3.4 CIPLA Limited: Business Strategy
11.3.4.1 Product Level Business Strategy
11.3.4.2 Service Level Business Strategy
11.3.5 SWOT Analysis of CIPLA Limited
Strengths
Weaknesses
Opportunities
Threats
11.3.6 Key Customers of CIPLA Limited
11.4 Dr. Reddy’s Laboratories
11.4.1 Company Profile
11.4.2 Dr. Reddy’s Laboratories in Pharma Manufacturing Value Chain
11.4.3 Dr. Reddy’s Laboratories: Financial Performance
11.4.4 Dr. Reddy’s Laboratories: Business Strategy
11.4.4.1 Product Level Business Strategy
11.4.4.2 Service Level Business Strategy
11.4.5 SWOT Analysis of Dr. Reddy’s Laboratories
Strengths
Weaknesses
Opportunities
Threats
11.5 Sun Pharmaceuticals Limited
11.5.1 Company Profile
11.5.2 Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
11.5.3 Sun Pharmaceuticals Limited: Financial Performance
11.5.4 Sun Pharmaceuticals Limited: Business Strategy
11.5.5 SWOT Analysis of Sun Pharmaceuticals Limited
Strengths
Weaknesses
Opportunities
Threats
11.5.6 Key customers of Sun Pharmaceuticals Limited
11.6 Lupin Limited
11.6.1 Company Profile
11.6.2 Lupin Limited in Pharma Manufacturing Value Chain
11.6.3 Lupin Limited: Financial Performance
11.6.4 Lupin Limited: Business Strategy
11.6.4.1 Product Level Strategy
11.6.5 SWOT Analysis of Lupin Limited
Strengths
Weaknesses
Opportunities
Threats
11.7 Aurobindo Pharma Limited
11.7.1 Company Profile
11.7.2 Aurobindo Pharmaceuticals in Pharma Manufacturing Value Chain
11.7.3 Aurobindo Pharmaceuticals: Financial Performance
11.7.4 Aurobindo Pharmaceuticals: Business Strategy
11.7.5 SWOT Analysis of Aurobindo Pharmaceuticals
Strengths
Weaknesses
Opportunities
Threats
11.8 Torrent Pharmaceuticals Limited
11.8.1 Company Profile
11.8.2 Torrent Pharmaceuticals in Pharma Manufacturing Value Chain
11.8.3 Torrent Pharmaceuticals: Financial Performance
11.8.4 Torrent Pharmaceuticals: Business Strategy
11.8.5 SWOT Analysis of Torrent Pharmaceuticals Limited
Strengths
Weaknesses
Opportunities
Threats
11.8.6 Key Customers of Torrent Pharmaceuticals
11.9 Divis Laboratories Limited
11.9.1 Company Profile
11.9.2 Divis Laboratories Limited in Pharma Manufacturing Value Chain
11.9.3 Divis Laboratories: Financial Performance
11.9.4 Divis Laboratories: Business Strategy
11.9.5 SWOT Analysis of Divis Laboratories Limited
Strengths
Weaknesses
Opportunities
Threats
11.10 IPCA Laboratories Limited
11.10.1 Company Profile
11.10.2 IPCA Laboratories Limited in Pharmaceutical Manufacturing Value Chain
11.10.3 IPCA Laboratories Limited: Financial Performance
11.10.4 IPCA Laboratories Limited: Business Strategy
11.10.5 SWOT Analysis of IPCA Laboratories Limited
Strengths
Weaknesses
Opportunities
Threats
11.1.10.6 Key Customers of IPCA Laboratories Limited
12. COMPETITIVE LANDSCAPE IN INDIAN PHARMACEUTICALS MARKET
12.1 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018
12.2 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue
13. ANALYSIS OF INDIA PHARMACEUTICALS MARKET
13.1 PESTLE Analysis of India Pharmaceuticals Market
13.2 Porter’s Five Forces Analysis of India Pharmaceuticals Market
13.3 SWOT Analysis of India Pharmaceuticals Market
Strengths
Weaknesses
Opportunities
Threats
14. CURRENT AND FUTURE TRENDS IN INDIAN PHARMACEUTICALS MARKET
Orphan Drugs
Biologics and Biosimilars
CURRENT TRENDS
1. Increasing Severity of Drug Price Controls
2. Greater Focus on Rare Diseases/Orphan Drugs
3. Increasing Development of Nucleic Acids as Therapeutics
4. Increasing Focus on Cell Therapy
5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
NOTES
COMPANY INFORMATION
Scope of the India Pharmaceuticals Industry Analysis and Trends 2023 Report
Research Methodology
2. INTRODUCTION OF INDIAN PHARMACEUTICALS MARKET
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Indian Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR INDIAN PHARMACEUTICALS MARKET
3.1 Rising & Ageing Population
3.2 Increasing Income Levels of Poor & Middle-Class Families
3.3 Drug Security
4. FORECAST FOR INDIA PHARMACEUTICALS MARKET 2023
4.1 Forecast for Asia Pacific Pharmaceuticals Market 2018-2023
4.1.1 Forecast for India Pharmaceuticals Market 2018-2023
5. EXIM SCENARIO IN INDIAN PHARMACEUTICALS MARKET
5.1 Export Scenario of Indian Pharmaceutical Products Market
5.1.1 Value of Pharmaceutical Products Exports from India 2008-09 to 2018-19 (Apr-Jan) in USD million
5.1.2 Top 5 Nations Importing Indian Pharmaceutical Products
5.2 Import Scenario of Indian Pharmaceutical Products Market
5.2.1 Value of Pharmaceutical Products Imports in India 2008-09 to 2018-19 (Apr-Jan) in USD million
5.2.2 Top 5 Nations Exporting Pharmaceutical Products to India
6. GROWTH DRIVERS AND INHIBITORS FOR INDIA PHARMACEUTICALS MARKET
7. POLICIES RELATED TO PHARMACEUTICALS INDUSTRY IN INDIA
7.1 Central Government Policies
7.1.1 Essential Commodities Act 1955
7.1.2 Drugs and Cosmetics Act 1940 (As amended in June 2005)
7.1.3 National Pharmaceutical Pricing Policy 2012
7.1.4 Drug Price Control Orders (DPCO)
7.1.5 Drug Policy 1986
7.1.6 Pharmaceutical Policy - 2002
7.2 Guidelines related to Clinical Trial in India
7.3 Guidelines related to Marketing in Indian Pharmaceuticals Industry
8. RISKS ASSOCIATED WITH INDIAN PHARMACEUTICALS MARKET
8.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
8.2 Risk of Commercial Success of New Products
8.3 Risk of Failed Research and Development Effort
8.4 Risk of Drug Price Controls
8.5 Risk of Failure to Comply with New Laws and Regulations
8.6 Risk of Quality Control During Complex Manufacturing Process
8.7 Risk of Cyber-Attacks and Data Breach
8.8 Risk of Volatile Currency Exchange Rates and Interest Rates
8.9 Risk of Unstable Global Political and Economic Conditions
9. INDUSTRY ASSOCIATIONS RELATED TO INDIAN PHARMACEUTICALS MARKET
9.1 Indian Drug Manufacturers' Association (IDMA)
9.2 Indian Pharma Machinery Manufacturers Association (IPMMA)
9.3 Indian Pharmaceutical Association (IPA)
9.4 Organisation of Pharmaceutical Producers of India (OPPI)
9.5 Association of Indian Medical Device Industry (AIMED)
10. GOVERNMENT BODIES RELATED TO INDIAN PHARMACEUTICALS MARKET
10.1 Department of Pharmaceuticals
10.2 Ministry of Chemicals & Fertilizers
10.3 National Pharmaceutical Pricing Authority (NPPA)
11. PROFILE OF KEY PLAYERS IN INDIAN PHARMACEUTICALS MARKET
11.1 Abbott India Limited
11.1.1 Company Profile
11.1.2 Abbott India in Pharma Manufacturing Value Chain
11.1.3 Abbott India: Financial Performance
11.1.4 Abbott India: Business Strategy
11.1.4.1 Product Level Strategy
11.1.5 SWOT Analysis of Abbott India
Strengths
Weaknesses
Opportunities
Threats
11.1.6 Key Customers of Abbott India
11.2 Biocon Limited
11.2.1 Company Profile
11.2.2 Biocon Limited in Pharmaceutical Manufacturing Value Chain
11.2.3 Biocon Limited: Financial Performance
11.2.4 Biocon Limited: Business Strategy
11.2.4.1 Product Level Business Strategy
11.2.4.2 Service Level Business Strategy
11.2.5 SWOT Analysis of Biocon Limited
Strengths
Weaknesses
Opportunities
Threats
11.2.6 Key Customers of Biocon Limited
11.3 CIPLA Limited
11.3.1 Company Profile
11.3.2 CIPLA Limited in Pharmaceutical Manufacturing Value Chain
11.3.3 CIPLA Limited: Financial Performance
11.3.4 CIPLA Limited: Business Strategy
11.3.4.1 Product Level Business Strategy
11.3.4.2 Service Level Business Strategy
11.3.5 SWOT Analysis of CIPLA Limited
Strengths
Weaknesses
Opportunities
Threats
11.3.6 Key Customers of CIPLA Limited
11.4 Dr. Reddy’s Laboratories
11.4.1 Company Profile
11.4.2 Dr. Reddy’s Laboratories in Pharma Manufacturing Value Chain
11.4.3 Dr. Reddy’s Laboratories: Financial Performance
11.4.4 Dr. Reddy’s Laboratories: Business Strategy
11.4.4.1 Product Level Business Strategy
11.4.4.2 Service Level Business Strategy
11.4.5 SWOT Analysis of Dr. Reddy’s Laboratories
Strengths
Weaknesses
Opportunities
Threats
11.5 Sun Pharmaceuticals Limited
11.5.1 Company Profile
11.5.2 Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
11.5.3 Sun Pharmaceuticals Limited: Financial Performance
11.5.4 Sun Pharmaceuticals Limited: Business Strategy
11.5.5 SWOT Analysis of Sun Pharmaceuticals Limited
Strengths
Weaknesses
Opportunities
Threats
11.5.6 Key customers of Sun Pharmaceuticals Limited
11.6 Lupin Limited
11.6.1 Company Profile
11.6.2 Lupin Limited in Pharma Manufacturing Value Chain
11.6.3 Lupin Limited: Financial Performance
11.6.4 Lupin Limited: Business Strategy
11.6.4.1 Product Level Strategy
11.6.5 SWOT Analysis of Lupin Limited
Strengths
Weaknesses
Opportunities
Threats
11.7 Aurobindo Pharma Limited
11.7.1 Company Profile
11.7.2 Aurobindo Pharmaceuticals in Pharma Manufacturing Value Chain
11.7.3 Aurobindo Pharmaceuticals: Financial Performance
11.7.4 Aurobindo Pharmaceuticals: Business Strategy
11.7.5 SWOT Analysis of Aurobindo Pharmaceuticals
Strengths
Weaknesses
Opportunities
Threats
11.8 Torrent Pharmaceuticals Limited
11.8.1 Company Profile
11.8.2 Torrent Pharmaceuticals in Pharma Manufacturing Value Chain
11.8.3 Torrent Pharmaceuticals: Financial Performance
11.8.4 Torrent Pharmaceuticals: Business Strategy
11.8.5 SWOT Analysis of Torrent Pharmaceuticals Limited
Strengths
Weaknesses
Opportunities
Threats
11.8.6 Key Customers of Torrent Pharmaceuticals
11.9 Divis Laboratories Limited
11.9.1 Company Profile
11.9.2 Divis Laboratories Limited in Pharma Manufacturing Value Chain
11.9.3 Divis Laboratories: Financial Performance
11.9.4 Divis Laboratories: Business Strategy
11.9.5 SWOT Analysis of Divis Laboratories Limited
Strengths
Weaknesses
Opportunities
Threats
11.10 IPCA Laboratories Limited
11.10.1 Company Profile
11.10.2 IPCA Laboratories Limited in Pharmaceutical Manufacturing Value Chain
11.10.3 IPCA Laboratories Limited: Financial Performance
11.10.4 IPCA Laboratories Limited: Business Strategy
11.10.5 SWOT Analysis of IPCA Laboratories Limited
Strengths
Weaknesses
Opportunities
Threats
11.1.10.6 Key Customers of IPCA Laboratories Limited
12. COMPETITIVE LANDSCAPE IN INDIAN PHARMACEUTICALS MARKET
12.1 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018
12.2 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue
13. ANALYSIS OF INDIA PHARMACEUTICALS MARKET
13.1 PESTLE Analysis of India Pharmaceuticals Market
13.2 Porter’s Five Forces Analysis of India Pharmaceuticals Market
13.3 SWOT Analysis of India Pharmaceuticals Market
Strengths
Weaknesses
Opportunities
Threats
14. CURRENT AND FUTURE TRENDS IN INDIAN PHARMACEUTICALS MARKET
Orphan Drugs
Biologics and Biosimilars
CURRENT TRENDS
1. Increasing Severity of Drug Price Controls
2. Greater Focus on Rare Diseases/Orphan Drugs
3. Increasing Development of Nucleic Acids as Therapeutics
4. Increasing Focus on Cell Therapy
5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
NOTES
COMPANY INFORMATION
LIST OF EXHIBITS
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Indian Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 India Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Purchasing Power Parity Based Per Capita GDP Forecast for India 2016-2023 (in USD)
Exhibit 4.1 Forecast for Asia Pacific Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.2 Country-wise Market Share in Asia Pacific Pharmaceuticals Market in 2017 (in %)
Exhibit 4.3 Population Forecast for India 2016-2023 (in millions)
Exhibit 4.4 India Pharmaceuticals Market Analysis
Exhibit 4.5 Forecast for India Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Export Value of Pharmaceutical Products from India (in USD million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
Exhibit 5.2 Top 5 Countries Importing Indian Pharmaceutical Products (in USD million) in FY 2017-18
Exhibit 5.3 Import Value of Pharmaceutical Products in India (in US$ million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
Exhibit 5.4 Top 5 Countries Exporting Pharmaceutical Products to India (in USD million) in FY 2017-18
Exhibit 6.1 Growth Drivers and Inhibitors for India Pharmaceuticals Market
Exhibit 7.1 Code for Marketing practices in Indian Pharmaceuticals Industry
Exhibit 8.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 9.1 Key information of IDMA
Exhibit 9.2 Contact details of IDMA
Exhibit 9.3 Key information of IPMMA
Exhibit 9.4 Contact details of IPMMA
Exhibit 9.5 Key Information of IPA
Exhibit 9.6 Contact details of IPA
Exhibit 9.7 Key information of OPPI
Exhibit 9.8 Contact details of OPPI
Exhibit 9.9 Contact information for AIMED
Exhibit 11.1 Key Information of Abbott India
Exhibit 11.2 Contact Information of Abbott India
Exhibit 11.3 Abbott India in Pharma Manufacturing Value chain
Exhibit 11.4 Abbott India Limited Revenue 2014-18 (in INR billion)
Exhibit 11.5 Abbott India Growth Rate 2014-2018 (in %)
Exhibit 11.6 Estimated Year wise Abbott India Revenue 2019-2023 (in INR billion)
Exhibit 11.7 Top performing brands of Abbott India 2018
Exhibit 11.8 Top New Products of Abbott India 2018
Exhibit 11.9 SWOT Analysis of Abbott India
Exhibit 11.10 Key Information of Biocon Limited
Exhibit 11.11 Contact Information of Biocon Limited
Exhibit 11.12 Biocon Ltd in Pharma Manufacturing Value Chain
Exhibit 11.13 Biocon Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.14 Year-wise Biocon Limited Revenue Growth 2013-18 (in %)
Exhibit 11.15 Category Wise Revenue Breakup for Biocon Limited 2018 (in INR billion)
Exhibit 11.16 Estimated Year wise Biocon Limited Revenue 2019-2023 (in INR billion)
Exhibit 11.17 Key Products of Biocon Limited
Exhibit 11.18 Key Services Offered by Biocon Limited
Exhibit 11.19 SWOT Analysis of Biocon Limited
Exhibit 11.20 Key Information of Cipla Limited
Exhibit 11.21 Contact Information of Cipla Limited
Exhibit 11.22 Cipla Limited in Pharmaceutical Manufacturing Value Chain
Exhibit 11.23 Cipla Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.24 Year-wise Cipla Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.25 Estimated Cipla Ltd. Revenue (in INR bn)
Exhibit 11.26 Key Products of Cipla Limited
Exhibit 11.27 Key Services of Cipla Limited
Exhibit 11.28 SWOT Analysis of Cipla Limited
Exhibit 11.29 Key Information of Dr. Reddy’s Laboratories
Exhibit 11.30 Contact Information of Dr. Reddy’s Laboratories
Exhibit 11.31 Dr. Reddy’s Laboratories in Pharmaceuticals Manufacturing Value Chain
Exhibit 11.32 Dr. Reddy’s Laboratories Revenue 2013-2017 (in INR million)
Exhibit 11.33 Year-wise Dr. Reddy’s Laboratories Revenue Growth 2014-17 (in %)
Exhibit 11.34 Dr. Reddy’s Laboratories Domestic Revenue 2014-2017 (in INR billion)
Exhibit 11.35 Year-wise Dr. Reddy’s Laboratories Domestic Revenue Growth 2015-2017 (in %)
Exhibit 11.36 Dr. Reddy’s Laboratories Export Revenue 2014-2017 (in INR billion)
Exhibit 11.37 Year-wise Dr. Reddy’s Laboratories Export Revenue Growth 2015-2017 (in %)
Exhibit 11.38 Source wise Revenue share of Dr. Reddy’s Lab. (in %)
Exhibit 11.39 Source wise Revenue CAGR growth forecast for Dr. Reddy’s Lab Ltd. 2018-23 (in %)
Exhibit 11.40 Forecast of Dr. Reddy’s Laboratories Ltd, 2018-23 (in INR bn)
Exhibit 11.41 Growth forecast of Domestic Revenue for Dr. Roddy’s Laboratories Ltd. 2018-23 (in INR bn)
Exhibit 11.42 Growth forecast of Export revenue for Dr. Reddy’s Laboratories ltd. Market 2018-23 (in INR bn)
Exhibit 11.43 Key Products of Dr. Reddy’s Laboratories
Exhibit 11.44 Key Services of Dr. Reddy’s Laboratories
Exhibit 11.45 SWOT Analysis of Dr. Reddy’s Laboratories
Exhibit 11.46 Key Information of Sun Pharmaceuticals Limited
Exhibit 11.47 Contact Information of Sun Pharmaceuticals Limited
Exhibit 11.48 Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
Exhibit 11.49 Sun Pharmaceuticals Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.50 Year-wise Sun Pharmaceuticals Limited Revenue Growth 2015-18 (in %)
Exhibit 11.51 Sun Pharmaceuticals Limited India Market Revenue 2014-2018 (in INR million)
Exhibit 11.52 Year-wise Sun Pharmaceuticals Limited India Market Revenue Growth 2015-2018 (in %)
Exhibit 11.53 Sun Pharmaceuticals Limited Export Revenue 2016-2018 (in INR billion)
Exhibit 11.54 Year-wise Sun Pharmaceuticals Limited US sales Revenue Growth (in %)
Exhibit 11.55 Sun Pharmaceuticals Industries Ltd, emerging markets Revenue (in INR bn)
Exhibit 11.56 Year wise sun Pharmaceutical Industries Ltd. Emerging markets Revenue growth (in %)
Exhibit 11.57 Sun Pharmaceuticals Industries Ltd. Rest of World Revenue (in INR bn)
Exhibit 11.58 Year wise Sun Pharmaceuticals Industries Ltd. Rest of World Revenue Growth (in %)
Exhibit 11.59 Source-wise Revenue Share of Sun Pharmaceutical Industries Ltd. (in %)
Exhibit 11.60 Source wise Revenue CAGR Growth Forecast for Sun Pharmaceutical Industries Ltd. 2019-23 (in %)
Exhibit 11.61 Forecast of Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.62 Forecast of India Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.63 Forecast of US Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.64 Forecast of Emerging Markets for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.65 Forecast of RoW Market for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.66 Key Products of Sun Pharmaceuticals Limited
Exhibit 11.67 SWOT Analysis of Sun Pharmaceuticals Limited
Exhibit 11.68 Key Information of Lupin Limited
Exhibit 11.69 Contact Information of Lupin Limited
Exhibit 11.70 Lupin Limited in Pharma Manufacturing Value Chain
Exhibit 11.71 Lupin Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.72 Year-wise Lupin Limited Revenue Growth 2014-18 (in %)
Exhibit 11.73 Lupin Limited India Market Revenue 20104-2018 (in INR billion)
Exhibit 11.74 Year-wise Lupin Limited Domestic Revenue Growth 2015-2018 (in %)
Exhibit 11.75 Lupin Limited Export Revenue 2010-2014 (in INR billion)
Exhibit 11.76 Year-wise Lupin Limited US Market Revenue Growth 2017-2018 (in %)
Exhibit 11.77 Lupin Ltd. Rest of World (RoW) Revenue (in INR bn)
Exhibit 11.78 Year wise Lupin Ltd. Rest of World Revenue Growth (in %)
Exhibit 11.79 Country wise Revenue share of Lupin Ltd. (in %)
Exhibit 11.80 Country wise Revenue CAGR Growth Forecast for Lupin Ltd. 2019-23 (in %)
Exhibit 11.81 Forecast of Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.82 Growth Forecast of India Market for Lupin Ltd. Market 2019-23 (in INR bn)
Exhibit 11.83 Growth Forecast of US market for Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.84 Growth Forecast of rest of world for Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.85 Key Products of Lupin Limited
Exhibit 11.86 SWOT Analysis of Lupin Limited
Exhibit 11.87 Key Information of Aurobindo Pharma Limited
Exhibit 11.88 Contact Information of Aurobindo Pharma Limited
Exhibit 11.89 Aurobindo Pharma Limited in Pharma Manufacturing Value Chain
Exhibit 11.90 Aurobindo Pharma Limited Revenue 2010-2014 (in INR billion)
Exhibit 11.91 Year-wise Aurobindo Pharma Limited Revenue Growth 2010-14 (in %)
Exhibit 11.92 Source wise revenue share of Aurobindo Pharma Ltd. (in %)
Exhibit 11.93 Source wise Revenue CAGR growth forecast for Aurobindo Pharma Ltd. 2018-23 (in %)
Exhibit 11.94 Forecast of Aurobindo Pharma Ltd. 2018-23 (in INR billions)
Exhibit 11.95 Growth Forecast of US Market for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 11.96 Growth forecast of Rest of World for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 11.97 SWOT Analysis of Aurobindo Pharmaceuticals
Exhibit 11.98 Key Information of Torrent Pharmaceuticals Limited
Exhibit 11.99 Contact Information of Torrent Pharmaceuticals Limited
Exhibit 11.100 Torrent Pharmaceuticals Limited in Pharma Manufacturing Value Chain
Exhibit 11.101 Torrent Pharmaceuticals Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.102 Year-wise Torrent Pharmaceuticals Limited Revenue Growth 2014-18 (in %)
Exhibit 11.103 Torrent Pharma Ltd, India Revenue (in INR bn)
Exhibit 11.104 Year wise Torrent Pharma Ltd. India Revenue Growth (in %)
Exhibit 11.105 Torrent Pharma Ltd. US sales Revenue (in INR bn)
Exhibit 11.106 Year wise Torrent Pharma Ltd. US sales Revenue Growth (in %)
Exhibit 11.107 Torrent Pharma Ltd. Germany Revenue (in INR bn)
Exhibit 11.108 Year wise Torrent Pharma Ltd. Germany Revenue Growth (in %)
Exhibit 11.109 Torrent Pharma Ltd. Brazil Revenue (in INR bn)
Exhibit 11.110 Year wise Torrent Pharma Ltd. Brazil Revenue Growth (in %)
Exhibit 11.111 Torrent Pharma Ltd. Others Revenue (in INR bn)
Exhibit 11.112 Year wise Torrent Pharma Ltd. Others Revenue Growth (in %)
Exhibit 11.113 Source Wise Revenue Share of Torrent Parma Ltd, (in %)
Exhibit 11.114 Source wise Revenue CAGR Growth Forecast for Torrent Pharma Ltd. 2019-23 (in %)
Exhibit 11.115 Forecast of Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.116 Forecast of India Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.117 Forecast of US Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.118 Forecast of Germany for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.119 Forecast of Brazil for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.120 Forecast of Others for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.121 Key Products of Torrent Pharmaceuticals Limited
Exhibit 11.122 SWOT Analysis of Torrent Pharmaceuticals Limited
Exhibit 11.123 Key Information of Divis Laboratories Limited
Exhibit 11.124 Contact Information of Divis Laboratories Limited
Exhibit 11.125 Divis Laboratories Limited in Pharma Manufacturing Value Chain
Exhibit 11.126 Divis Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.127 Year-wise Divis Laboratories Limited Revenue Growth 2014-18 (in %)
Exhibit 11.128 Divis Lab Ltd, Export Revenue (in INR bn)
Exhibit 11.129 Year wise Divis Lab Ltd. Export Revenue Growth (in %)
Exhibit 11.130 Divis Lab Ltd. India Sales Revenue (in INR bn)
Exhibit 11.131 Year wise Divis Lab Ltd. India Sales Revenue growth (in %)
Exhibit 11.132 Source wise Revenue Share of Divis Lab Ltd. (%)
Exhibit 11.133 Source wise Revenue CAGR Growth Forecast for Divis Lab Ltd. 2019-23 (in %)
Exhibit 11.134 Forecast of Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.135 Forecast of Rest of World Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.136 Forecast of India Market Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.137 Key Products of Divis Laboratories Limited
Exhibit 11.138 SWOT Analysis of Divis Laboratories Limited
Exhibit 11.139 Key Information of Ipca Laboratories Limited
Exhibit 11.140 Contact details of Ipca Laboratories Limited
Exhibit 11.141 Laboratories Limited in Pharma Manufacturing Value Chain
Exhibit 11.142 IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.143 Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.144 Estimated Year wise IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.145 Estimated Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.146 IPCA Laboratories Limited Revenue by Geography 2014 (in INR billion)
Exhibit 11.147 Year wise IPCA Lab Ltd. Export Sales Revenue Growth (in %)
Exhibit 11.148 Source wise Revenue share of IPCA Lab Ltd. (in %)
Exhibit 11.149 Source wise Revenue CAGR growth forecast for IPCA Lab. Ltd. 2019-23 (in %)
Exhibit 11.150 Forecast of IPCA Lab. Ltd. 2019-23 (in INR bn)
Exhibit 11.151 Forecast of India Market Revenue for IPCA Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.152 Forecast of Export Market Revenue for IPCA Lab ltd. 2019-23 (in INR bn)
Exhibit 11.153 Key Products of IPCA Laboratories Limited
Exhibit 11.154 Key Services of IPCA Laboratories Limited
Exhibit 11.155 SWOT Analysis of IPCA Laboratories Limited
Exhibit 11.156 Key Customers of IPCA Laboratories Limited
Exhibit 12.1 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018 (in INR billion)
Exhibit 12.2 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue (in INR billion)
Exhibit 13.1 PESTEL Analysis of the Indian Pharmaceuticals Industry
Exhibit 13.2 Porter’s Five Forces Analysis for India Pharmaceuticals Market
Exhibit 13.3 SWOT Analysis for India Pharmaceuticals Market
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Indian Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 India Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Purchasing Power Parity Based Per Capita GDP Forecast for India 2016-2023 (in USD)
Exhibit 4.1 Forecast for Asia Pacific Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.2 Country-wise Market Share in Asia Pacific Pharmaceuticals Market in 2017 (in %)
Exhibit 4.3 Population Forecast for India 2016-2023 (in millions)
Exhibit 4.4 India Pharmaceuticals Market Analysis
Exhibit 4.5 Forecast for India Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Export Value of Pharmaceutical Products from India (in USD million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
Exhibit 5.2 Top 5 Countries Importing Indian Pharmaceutical Products (in USD million) in FY 2017-18
Exhibit 5.3 Import Value of Pharmaceutical Products in India (in US$ million) from FY 2008-09 to FY 2018-19 (Apr-Jan)
Exhibit 5.4 Top 5 Countries Exporting Pharmaceutical Products to India (in USD million) in FY 2017-18
Exhibit 6.1 Growth Drivers and Inhibitors for India Pharmaceuticals Market
Exhibit 7.1 Code for Marketing practices in Indian Pharmaceuticals Industry
Exhibit 8.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 9.1 Key information of IDMA
Exhibit 9.2 Contact details of IDMA
Exhibit 9.3 Key information of IPMMA
Exhibit 9.4 Contact details of IPMMA
Exhibit 9.5 Key Information of IPA
Exhibit 9.6 Contact details of IPA
Exhibit 9.7 Key information of OPPI
Exhibit 9.8 Contact details of OPPI
Exhibit 9.9 Contact information for AIMED
Exhibit 11.1 Key Information of Abbott India
Exhibit 11.2 Contact Information of Abbott India
Exhibit 11.3 Abbott India in Pharma Manufacturing Value chain
Exhibit 11.4 Abbott India Limited Revenue 2014-18 (in INR billion)
Exhibit 11.5 Abbott India Growth Rate 2014-2018 (in %)
Exhibit 11.6 Estimated Year wise Abbott India Revenue 2019-2023 (in INR billion)
Exhibit 11.7 Top performing brands of Abbott India 2018
Exhibit 11.8 Top New Products of Abbott India 2018
Exhibit 11.9 SWOT Analysis of Abbott India
Exhibit 11.10 Key Information of Biocon Limited
Exhibit 11.11 Contact Information of Biocon Limited
Exhibit 11.12 Biocon Ltd in Pharma Manufacturing Value Chain
Exhibit 11.13 Biocon Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.14 Year-wise Biocon Limited Revenue Growth 2013-18 (in %)
Exhibit 11.15 Category Wise Revenue Breakup for Biocon Limited 2018 (in INR billion)
Exhibit 11.16 Estimated Year wise Biocon Limited Revenue 2019-2023 (in INR billion)
Exhibit 11.17 Key Products of Biocon Limited
Exhibit 11.18 Key Services Offered by Biocon Limited
Exhibit 11.19 SWOT Analysis of Biocon Limited
Exhibit 11.20 Key Information of Cipla Limited
Exhibit 11.21 Contact Information of Cipla Limited
Exhibit 11.22 Cipla Limited in Pharmaceutical Manufacturing Value Chain
Exhibit 11.23 Cipla Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.24 Year-wise Cipla Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.25 Estimated Cipla Ltd. Revenue (in INR bn)
Exhibit 11.26 Key Products of Cipla Limited
Exhibit 11.27 Key Services of Cipla Limited
Exhibit 11.28 SWOT Analysis of Cipla Limited
Exhibit 11.29 Key Information of Dr. Reddy’s Laboratories
Exhibit 11.30 Contact Information of Dr. Reddy’s Laboratories
Exhibit 11.31 Dr. Reddy’s Laboratories in Pharmaceuticals Manufacturing Value Chain
Exhibit 11.32 Dr. Reddy’s Laboratories Revenue 2013-2017 (in INR million)
Exhibit 11.33 Year-wise Dr. Reddy’s Laboratories Revenue Growth 2014-17 (in %)
Exhibit 11.34 Dr. Reddy’s Laboratories Domestic Revenue 2014-2017 (in INR billion)
Exhibit 11.35 Year-wise Dr. Reddy’s Laboratories Domestic Revenue Growth 2015-2017 (in %)
Exhibit 11.36 Dr. Reddy’s Laboratories Export Revenue 2014-2017 (in INR billion)
Exhibit 11.37 Year-wise Dr. Reddy’s Laboratories Export Revenue Growth 2015-2017 (in %)
Exhibit 11.38 Source wise Revenue share of Dr. Reddy’s Lab. (in %)
Exhibit 11.39 Source wise Revenue CAGR growth forecast for Dr. Reddy’s Lab Ltd. 2018-23 (in %)
Exhibit 11.40 Forecast of Dr. Reddy’s Laboratories Ltd, 2018-23 (in INR bn)
Exhibit 11.41 Growth forecast of Domestic Revenue for Dr. Roddy’s Laboratories Ltd. 2018-23 (in INR bn)
Exhibit 11.42 Growth forecast of Export revenue for Dr. Reddy’s Laboratories ltd. Market 2018-23 (in INR bn)
Exhibit 11.43 Key Products of Dr. Reddy’s Laboratories
Exhibit 11.44 Key Services of Dr. Reddy’s Laboratories
Exhibit 11.45 SWOT Analysis of Dr. Reddy’s Laboratories
Exhibit 11.46 Key Information of Sun Pharmaceuticals Limited
Exhibit 11.47 Contact Information of Sun Pharmaceuticals Limited
Exhibit 11.48 Sun Pharmaceuticals Limited in Pharma Manufacturing Value Chain
Exhibit 11.49 Sun Pharmaceuticals Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.50 Year-wise Sun Pharmaceuticals Limited Revenue Growth 2015-18 (in %)
Exhibit 11.51 Sun Pharmaceuticals Limited India Market Revenue 2014-2018 (in INR million)
Exhibit 11.52 Year-wise Sun Pharmaceuticals Limited India Market Revenue Growth 2015-2018 (in %)
Exhibit 11.53 Sun Pharmaceuticals Limited Export Revenue 2016-2018 (in INR billion)
Exhibit 11.54 Year-wise Sun Pharmaceuticals Limited US sales Revenue Growth (in %)
Exhibit 11.55 Sun Pharmaceuticals Industries Ltd, emerging markets Revenue (in INR bn)
Exhibit 11.56 Year wise sun Pharmaceutical Industries Ltd. Emerging markets Revenue growth (in %)
Exhibit 11.57 Sun Pharmaceuticals Industries Ltd. Rest of World Revenue (in INR bn)
Exhibit 11.58 Year wise Sun Pharmaceuticals Industries Ltd. Rest of World Revenue Growth (in %)
Exhibit 11.59 Source-wise Revenue Share of Sun Pharmaceutical Industries Ltd. (in %)
Exhibit 11.60 Source wise Revenue CAGR Growth Forecast for Sun Pharmaceutical Industries Ltd. 2019-23 (in %)
Exhibit 11.61 Forecast of Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.62 Forecast of India Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.63 Forecast of US Market Revenue for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.64 Forecast of Emerging Markets for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.65 Forecast of RoW Market for Sun Pharmaceutical Industries Ltd. 2019-23 (in INR bn)
Exhibit 11.66 Key Products of Sun Pharmaceuticals Limited
Exhibit 11.67 SWOT Analysis of Sun Pharmaceuticals Limited
Exhibit 11.68 Key Information of Lupin Limited
Exhibit 11.69 Contact Information of Lupin Limited
Exhibit 11.70 Lupin Limited in Pharma Manufacturing Value Chain
Exhibit 11.71 Lupin Limited Revenue 2014-2018 (in INR billion)
Exhibit 11.72 Year-wise Lupin Limited Revenue Growth 2014-18 (in %)
Exhibit 11.73 Lupin Limited India Market Revenue 20104-2018 (in INR billion)
Exhibit 11.74 Year-wise Lupin Limited Domestic Revenue Growth 2015-2018 (in %)
Exhibit 11.75 Lupin Limited Export Revenue 2010-2014 (in INR billion)
Exhibit 11.76 Year-wise Lupin Limited US Market Revenue Growth 2017-2018 (in %)
Exhibit 11.77 Lupin Ltd. Rest of World (RoW) Revenue (in INR bn)
Exhibit 11.78 Year wise Lupin Ltd. Rest of World Revenue Growth (in %)
Exhibit 11.79 Country wise Revenue share of Lupin Ltd. (in %)
Exhibit 11.80 Country wise Revenue CAGR Growth Forecast for Lupin Ltd. 2019-23 (in %)
Exhibit 11.81 Forecast of Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.82 Growth Forecast of India Market for Lupin Ltd. Market 2019-23 (in INR bn)
Exhibit 11.83 Growth Forecast of US market for Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.84 Growth Forecast of rest of world for Lupin Ltd. 2019-23 (in INR bn)
Exhibit 11.85 Key Products of Lupin Limited
Exhibit 11.86 SWOT Analysis of Lupin Limited
Exhibit 11.87 Key Information of Aurobindo Pharma Limited
Exhibit 11.88 Contact Information of Aurobindo Pharma Limited
Exhibit 11.89 Aurobindo Pharma Limited in Pharma Manufacturing Value Chain
Exhibit 11.90 Aurobindo Pharma Limited Revenue 2010-2014 (in INR billion)
Exhibit 11.91 Year-wise Aurobindo Pharma Limited Revenue Growth 2010-14 (in %)
Exhibit 11.92 Source wise revenue share of Aurobindo Pharma Ltd. (in %)
Exhibit 11.93 Source wise Revenue CAGR growth forecast for Aurobindo Pharma Ltd. 2018-23 (in %)
Exhibit 11.94 Forecast of Aurobindo Pharma Ltd. 2018-23 (in INR billions)
Exhibit 11.95 Growth Forecast of US Market for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 11.96 Growth forecast of Rest of World for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 11.97 SWOT Analysis of Aurobindo Pharmaceuticals
Exhibit 11.98 Key Information of Torrent Pharmaceuticals Limited
Exhibit 11.99 Contact Information of Torrent Pharmaceuticals Limited
Exhibit 11.100 Torrent Pharmaceuticals Limited in Pharma Manufacturing Value Chain
Exhibit 11.101 Torrent Pharmaceuticals Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.102 Year-wise Torrent Pharmaceuticals Limited Revenue Growth 2014-18 (in %)
Exhibit 11.103 Torrent Pharma Ltd, India Revenue (in INR bn)
Exhibit 11.104 Year wise Torrent Pharma Ltd. India Revenue Growth (in %)
Exhibit 11.105 Torrent Pharma Ltd. US sales Revenue (in INR bn)
Exhibit 11.106 Year wise Torrent Pharma Ltd. US sales Revenue Growth (in %)
Exhibit 11.107 Torrent Pharma Ltd. Germany Revenue (in INR bn)
Exhibit 11.108 Year wise Torrent Pharma Ltd. Germany Revenue Growth (in %)
Exhibit 11.109 Torrent Pharma Ltd. Brazil Revenue (in INR bn)
Exhibit 11.110 Year wise Torrent Pharma Ltd. Brazil Revenue Growth (in %)
Exhibit 11.111 Torrent Pharma Ltd. Others Revenue (in INR bn)
Exhibit 11.112 Year wise Torrent Pharma Ltd. Others Revenue Growth (in %)
Exhibit 11.113 Source Wise Revenue Share of Torrent Parma Ltd, (in %)
Exhibit 11.114 Source wise Revenue CAGR Growth Forecast for Torrent Pharma Ltd. 2019-23 (in %)
Exhibit 11.115 Forecast of Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.116 Forecast of India Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.117 Forecast of US Market Revenue for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.118 Forecast of Germany for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.119 Forecast of Brazil for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.120 Forecast of Others for Torrent Pharma Ltd. 2019-23 (in INR bn)
Exhibit 11.121 Key Products of Torrent Pharmaceuticals Limited
Exhibit 11.122 SWOT Analysis of Torrent Pharmaceuticals Limited
Exhibit 11.123 Key Information of Divis Laboratories Limited
Exhibit 11.124 Contact Information of Divis Laboratories Limited
Exhibit 11.125 Divis Laboratories Limited in Pharma Manufacturing Value Chain
Exhibit 11.126 Divis Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.127 Year-wise Divis Laboratories Limited Revenue Growth 2014-18 (in %)
Exhibit 11.128 Divis Lab Ltd, Export Revenue (in INR bn)
Exhibit 11.129 Year wise Divis Lab Ltd. Export Revenue Growth (in %)
Exhibit 11.130 Divis Lab Ltd. India Sales Revenue (in INR bn)
Exhibit 11.131 Year wise Divis Lab Ltd. India Sales Revenue growth (in %)
Exhibit 11.132 Source wise Revenue Share of Divis Lab Ltd. (%)
Exhibit 11.133 Source wise Revenue CAGR Growth Forecast for Divis Lab Ltd. 2019-23 (in %)
Exhibit 11.134 Forecast of Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.135 Forecast of Rest of World Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.136 Forecast of India Market Revenue for Divis Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.137 Key Products of Divis Laboratories Limited
Exhibit 11.138 SWOT Analysis of Divis Laboratories Limited
Exhibit 11.139 Key Information of Ipca Laboratories Limited
Exhibit 11.140 Contact details of Ipca Laboratories Limited
Exhibit 11.141 Laboratories Limited in Pharma Manufacturing Value Chain
Exhibit 11.142 IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.143 Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.144 Estimated Year wise IPCA Laboratories Limited Revenue 2013-2018 (in INR billion)
Exhibit 11.145 Estimated Year-wise IPCA Laboratories Limited Revenue Growth 2014-2018 (in %)
Exhibit 11.146 IPCA Laboratories Limited Revenue by Geography 2014 (in INR billion)
Exhibit 11.147 Year wise IPCA Lab Ltd. Export Sales Revenue Growth (in %)
Exhibit 11.148 Source wise Revenue share of IPCA Lab Ltd. (in %)
Exhibit 11.149 Source wise Revenue CAGR growth forecast for IPCA Lab. Ltd. 2019-23 (in %)
Exhibit 11.150 Forecast of IPCA Lab. Ltd. 2019-23 (in INR bn)
Exhibit 11.151 Forecast of India Market Revenue for IPCA Lab Ltd. 2019-23 (in INR bn)
Exhibit 11.152 Forecast of Export Market Revenue for IPCA Lab ltd. 2019-23 (in INR bn)
Exhibit 11.153 Key Products of IPCA Laboratories Limited
Exhibit 11.154 Key Services of IPCA Laboratories Limited
Exhibit 11.155 SWOT Analysis of IPCA Laboratories Limited
Exhibit 11.156 Key Customers of IPCA Laboratories Limited
Exhibit 12.1 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Overall Revenue for FY2018 (in INR billion)
Exhibit 12.2 Competitive Landscape Among Key 10 Indian Pharmaceuticals Companies by Forecast Revenue (in INR billion)
Exhibit 13.1 PESTEL Analysis of the Indian Pharmaceuticals Industry
Exhibit 13.2 Porter’s Five Forces Analysis for India Pharmaceuticals Market
Exhibit 13.3 SWOT Analysis for India Pharmaceuticals Market
